The Food and Drug Administration on Tuesday approved Sanofi and Regeneron Pharmaceutical's drug Dupixent as a treatment for moderate to severe eczema.
Here are four things to know.
1. Dupixent, which is injected under the skin, is intended for patients who do not respond to traditional topical eczema treatments, according to the FDA.
2. The drug has a list price of $37,000 a year, according to The New York Times.
3. To limit public scrutiny of the drug's price, Sanofi and Regeneron communicated directly with insurers about pricing and other details prior to winning FDA approval, according to the report.
4. Steve Miller, MD, CMO of Express Scripts, told The New York Times the drugmakers had a lot of negotiating power when setting Dupixent's list price since there is good evidence of the drug's efficacy, and the treatment has no competition on the market.
More articles on supply chain:
3 ways payers and providers can collaborate to lower drug costs
8 things to know about compassionate use, right-to-try laws
Genesis Automation secures GPO contract with Vizient